|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1092 GBX | +9.20% |
|
+4.00% | -49.21% |
| 07-07 | WINNERS & LOSERS: Beauty Tech ups guidance; Ixico to beat expectations | AN |
| 07-02 | WINNERS & LOSERS: Capricorn jumps after agreeing to Genel takeover | AN |
| Market Cap | 5.04M 5.74M 4.66M 4.29M 8.12M 549M 8.27M 55.58M 21.8M 270M 21.56M 21.09M 932M | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 9.9M 11.28M 9.17M 8.43M 15.95M 1.08B 16.26M 109M 42.85M 530M 42.37M 41.45M 1.83B | EV / Sales 2026 * |
5.33x | EV / Sales 2027 * | - |
| Free-Float |
90.13% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Oxford BioDynamics Plc
| 1 day | +9.20% | ||
| 1 week | +4.00% | ||
| Current month | +9.20% | ||
| 1 month | -39.33% | ||
| 3 months | -42.53% | ||
| 6 months | -57.18% | ||
| Current year | -49.21% |
| 1 week | 0.09 |  | 0.12 |
| 1 month | 0.08 | | 0.19 |
| Current year | 0.08 | | 0.34 |
| 1 year | 0.08 | | 0.78 |
| 3 years | 0.08 | | 52 |
| 5 years | 0.08 | | 62.8 |
| 10 years | 0.08 | | 278.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 64 | 2007-06-07 | |
Richard Compton
CEO | Chief Executive Officer | - | 2026-06-29 |
Paul Stockdale
DFI | Director of Finance/CFO | - | 2017-09-14 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 2007-06-07 | |
Paul Stockdale
BRD | Director/Board Member | - | 2017-09-14 |
David Holbrook
BRD | Director/Board Member | 65 | 2019-04-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 11-09 | Free | Founder | 15,000,000 | 0.7663% | ||
| 11-09 | Free | Chairman | 4,400,000 | 0.2248% | ||
| 11-09 | Free | Executive/Senior Manager | 15,000,000 | 0.7663% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.20% | +4.00% | -58.00% | -99.06% | 5.74M | |
| -1.77% | -1.42% | +12.57% | -24.79% | 3.26B | |
| -0.69% | -1.88% | +3.58% | -82.65% | 1.99B | |
| -2.86% | -2.03% | -12.76% | -16.42% | 310M | |
| -4.05% | -4.82% | -47.57% | - | 50.76M | |
| Average | -0.03% | -3.75% | -20.44% | -55.73% | 1.12B | |
| Weighted average by Cap. | -1.46% | -1.65% | +7.37% | -45.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.86M 2.12M 1.72M 1.58M 2.99M 203M 3.05M 20.49M 8.04M 99.46M 7.95M 7.77M 343M | - |
| Net income | - | - |
| Net Debt | 4.86M 5.54M 4.5M 4.14M 7.84M 531M 7.99M 53.67M 21.05M 261M 20.82M 20.36M 900M | - |
Employees
37
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | GBX 0.1092 | +9.20% | 4,320,507 |
| 26-07-13 | GBX 0.1000 | 0.00% | 17,183,646 |
| 26-07-10 | GBX 0.1000 | -9.09% | 56,440,520 |
| 26-07-09 | GBX 0.1100 | +4.76% | 22,020,452 |
| 26-07-08 | GBX 0.1050 | 0.00% | 18,295,185 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.001000GBP
Average target price
0.0100GBP
Spread / Average Target
+900.00%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OBD Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
